TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14564594

Group type: EXPERIMENTAL
Intervention: Epidural injection of 8 ml of physiological saline after spinal hyperbaric tetracaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural injection of 8 ml of physiological saline after spinal isobaric tetracaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal hyperbaric tetracaine without epidural injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal isobaric tetracaine without epidural injection
Number of subjects: 40
Study: 8638527

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of the renin-angiotensin system
Number of subjects: 0
Study: 1832634

Group type: EXPERIMENTAL
Intervention: Blind biopsy using a 2.0-mm Tru-cut needle
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laparoscopy-guided biopsy using a 2.0-mm Tru-cut needle
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall incidence of postbiopsy hematoma formation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups (Blind and Laparoscopy-guided)
Number of subjects: 120
Study: 6349142

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 302

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 302
Study: 31005178

Group type: EXPERIMENTAL
Intervention: 2D transthoracic echocardiography (2D TTE)
Number of subjects: 259
Study: 30125448

Group type: EXPERIMENTAL
Intervention: Study 1 (n=23): Key features of work well-being identified as workload (n=14), job satisfaction (n=13), and support (n=13).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Study 2 (n=25): Highest rated elements included feeling valued, respect, support, work-life balance, and workplace culture.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Study 3 (n=17): Mean score for central narrative was 7.88 and for peripheral narrative was 7.38.
Number of subjects: 65
Study: 27448700

Group type: EXPERIMENTAL
Intervention: High intensity atorvastatin (40 mg/day)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Moderate intensity atorvastatin (20 mg/day)
Number of subjects: 591
Study: 24593323

Group type: EXPERIMENTAL
Intervention: 20 U of NTC
Number of subjects: 272

Group type: COMPARATOR
Intervention: onabotulinumtoxin A
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: NTC
Number of subjects: 272
Study: 21915941

Group type: EXPERIMENTAL
Intervention: Spatial Fourier-ICA applied to resting-state and naturalistic stimulation MEG data
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spatial Fourier-ICA
Number of subjects: 9
Study: 20164274

Group type: EXPERIMENTAL
Intervention: Tampon with a four‐winged apertured film cover
Number of subjects: 69

Group type: COMPARATOR
Intervention: Commercial tampon with a nonwoven cover
Number of subjects: 69
Study: 17283260

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 893

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d
Number of subjects: 893
Study: 15629605

Group type: EXPERIMENTAL
Intervention: Radiotherapy with hyperthermia (minimum of five sessions, 60 min each, once per week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 110
Study: 11869407

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 110
Study: 10198862

Group type: EXPERIMENTAL
Intervention: Asymmetric corneal tunnel incisions with an L‐shaped entrance and a concave exit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional symmetric linear incisions
Number of subjects: 0
Study: 7780258

Group type: EXPERIMENTAL
Intervention: Automatic needle insertion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Manual pen
Number of subjects: 18
Study: 2184874

Group type: EXPERIMENTAL
Intervention: Sensory integration (SI) sessions, about 13 weekly sessions, each of 1 hour duration
Number of subjects: 74

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 74
Study: 385456

Group type: EXPERIMENTAL
Intervention: Hydrocortisate treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 30955043

Group type: EXPERIMENTAL
Intervention: Active working memory training
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control working memory training
Number of subjects: 123
Study: 27569433

Group type: EXPERIMENTAL
Intervention: Bladder training video
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 150
Study: 24687433

Group type: EXPERIMENTAL
Intervention: Cemented highly porous metal tibia
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Uncemented highly porous metal tibia
Number of subjects: 397

Group type: COMPARATOR
Intervention: Traditional modular cemented tibia
Number of subjects: 397
Study: 23827078

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: methycobal
Number of subjects: 120
Study: 21917766

Group type: COMPARATOR
Intervention: ELND005 250 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 19074463

Group type: EXPERIMENTAL
Intervention: L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/‐0.22 GBq; 54.6+/‐5.9 mCi)
Number of subjects: 42

Group type: COMPARATOR
Intervention: rhTSH stimulation; 21 patients received (131)I (1.97+/‐0.18 GBq; 53.2+/‐4.9 mCi) 24 h after rhTSH (0.9 mg)
Number of subjects: 42
Study: 16696817

Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg o.d.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg b.d.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15291218

Group type: EXPERIMENTAL
Intervention: Provision of information regarding the relationship between choice and outcome
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct contact with the underlying contingencies
Number of subjects: 40
Study: 11737382

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg per day)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Both groups (Itraconazole and Placebo)
Number of subjects: 374
Study: 9764979

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment for 24 weeks
Number of subjects: 30
Study: 7889617

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg rhIGF‐I
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3148471

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol
Number of subjects: 0
Study: 30388273

Group type: EXPERIMENTAL
Intervention: Addressing Tobacco Through Organizational Change (ATTOC)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 456
Study: 30058418

Group type: EXPERIMENTAL
Intervention: Vitamin C (VitC) treatment group
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Vitamin C (VitC) non-treatment group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (patients without EMs)
Number of subjects: 280
Study: 27401361

Group type: EXPERIMENTAL
Intervention: Assessment of Burden of COPD (ABC) tool
Number of subjects: 357

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 357
Study: 24667180

Group type: EXPERIMENTAL
Intervention: Reminiscence and creative activity intervention delivered by retired senior volunteers (RSVs) through three home visits.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supportive telephone calls by research staff (Control group).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reminiscence and creative activity intervention delivered by RSVs.
Number of subjects: 45
Study: 22850141

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study: 20951287

Group type: EXPERIMENTAL
Intervention: EndoVac irrigation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional needle irrigation
Number of subjects: 7
Study: 17484941

Group type: EXPERIMENTAL
Intervention: Baseline interviews completed within 1 month of victimization
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Predictors of posttraumatic distress
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Comparison of distress levels
Number of subjects: 541
Study: 15077292

Group type: EXPERIMENTAL
Intervention: Infliximab + MTX
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 24
Study: 10869583

Group type: EXPERIMENTAL
Intervention: Patient with SMA-proper lesion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 6
Study: 9377616

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voglibose 0.3 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acarbose and Voglibose
Number of subjects: 20
Study: 8385844

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (two doses + booster)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (booster dose)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Convalescents and ISG recipients
Number of subjects: 79
Study: 3081020

Group type: EXPERIMENTAL
Intervention: Nitroglycerine (group II) 3.6 +/- 0.6 micrograms kg‐1 min‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Verapamil (group III) 31.1 +/- 2.6 micrograms kg‐1 min‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nifedipine (group IV) 1.7 +/- 0.2 microgram kg‐1 min‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (I: no vasodilator)
Number of subjects: 80
Study: 2455121

Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 12
Study: 31228383

Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including exercise therapy, drinking balneotherapy, multivitamins, vibrotherapy, chromotherapy, melody therapy, aromatherapy, aeroionotherapy
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 330
Study: 28182741

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Human metapneumovirus (hMPV)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Risk factors for RSV
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Risk factors for influenza A
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Risk factors for HPIV-3 infection
Number of subjects: 406
Study: 25420207

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 or 2 mg/d)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 23279594

Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Karl Storz (KS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 8
Study: 21663680

Group type: EXPERIMENTAL
Intervention: High calorie high protein supplement for forty days in addition to their diet of choice
Number of subjects: 44

Group type: COMPARATOR
Intervention: High protein milk during hospital stay in addition to their diet of choice
Number of subjects: 44
Study: 18254132

Group type: EXPERIMENTAL
Intervention: Nuchal scan at 10 to 14 + 6 weeks followed by detailed morphology scan at 12 to 14 + 6 weeks
Number of subjects: 7642

Group type: COMPARATOR
Intervention: Nuchal scan at 10 to 14 + 6 weeks followed by routine 16‐23‐week scan
Number of subjects: 7642
Study: 16836625

Group type: EXPERIMENTAL
Intervention: Disease management program including screening, patient education, drug therapy with paroxetine, and supportive contacts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group) where general practitioners were blind to the screening results and treatment was not restricted.
Number of subjects: 0
Study: 15523172

Group type: EXPERIMENTAL
Intervention: Heparin group (20-ml saline-flush followed by 2 ml of 1,000 U/ml heparin-lock)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline group (20-ml saline-flush once a day for each lumen)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 11199329

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: CD14 CC genotype
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: TNF-alpha AA genotype
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: IL-6-174 CC genotype
Number of subjects: 375
Study: 9261525

Group type: EXPERIMENTAL
Intervention: Granisetron, dexamethasone, and their combination (exact dosages and duration not specified)
Number of subjects: 395
Study: 8392825

Group type: EXPERIMENTAL
Intervention: 0.5 mg granisetron
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 2 mg granisetron
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 4 mg granisetron
Number of subjects: 85
Study: 3080282

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms qid (without antacid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms qid (with limited antacid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid (with limited antacid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28462574

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (12 weeks, 3 times per week, 45-60 minutes per session)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 26704270

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 34
Study: 25906974

Group type: EXPERIMENTAL
Intervention: Personalized dosing strategy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standardized dosing strategy
Number of subjects: 120
Study: 23550716

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES 130 kDa/0.4)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer's acetate (RAC)
Number of subjects: 30
Study: 20589264

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide with light activation (diode lamp, Luma Cool)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrogen peroxide without light activation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Comparison of light-treated hemi-arch
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of non-light-treated hemi-arch
Number of subjects: 21
Study: 18221925

Group type: EXPERIMENTAL
Intervention: Routine episiotomy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Selective episiotomy
Number of subjects: 446
Study: 17019663

Group type: EXPERIMENTAL
Intervention: Early warfarin administration (12 hr after TCC placement) with ticlopidine 250 mg/die
Number of subjects: 144

Group type: COMPARATOR
Intervention: Warfarin administration after the first thrombosis/malfunction episode with ticlopidine 250 mg/die
Number of subjects: 144
Study: 12730452

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (n = 9; age, 2-5 mo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Breastfeeding plus modest supplementation with cow's milk-based formula (n = 16; age, 3-4 mo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exclusive formula feeding (n = 4; age, 3-4 mo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding plus complementary foods (n = 16; age, 7 mo)
Number of subjects: 45
Study: 10735893

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (Hfx RT) with concurrent low-dose daily cisplatin (6 mg/m²)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy (Hfx RT) alone
Number of subjects: 130
Study: 9014627

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 82
Study: 1389517

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and folinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 0
Study: 2412041

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol 100 mg twice daily for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10
Study: 31433785

Group type: EXPERIMENTAL
Intervention: Treadmill training (TT) at moderate intensity (60% HRR), 2 sessions of 30 minutes/week for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treadmill training)
Number of subjects: 20
Study: 29906251

Group type: EXPERIMENTAL
Intervention: TMZ/veliparib
Number of subjects: 104

Group type: COMPARATOR
Intervention: TMZ/placebo
Number of subjects: 104
Study: 26749220

Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 3 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g (multiple-dose, once daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 9 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI)
Number of subjects: 21
Study: 24466245

Group type: COMPARATOR
Intervention: Chloroquine (CQ) 25 mg/kg
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 50 mg/kg
Number of subjects: 452
Study: 23143762

Group type: EXPERIMENTAL
Intervention: Surgery (OP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy (OP & RT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No local therapy (noL)
Number of subjects: 80
Study: 19022282

Group type: EXPERIMENTAL
Intervention: Nutrition Facts Label pocket card and video explaining card use
Number of subjects: 56

Group type: COMPARATOR
Intervention: Written materials (control group)
Number of subjects: 56
Study: 17483007

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) portioned into five meals per day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) between 0900 and 1100 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) between 1800 and 2000 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d)
Number of subjects: 12
Study: 14750100

Group type: EXPERIMENTAL
Intervention: Extended dialysis for 12 hours
Number of subjects: 39

Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration (CVVH) for 24 hours
Number of subjects: 39
Study: 11591234

Group type: COMPARATOR
Intervention: MCT meal (15 g fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Linoleate meal (50 g fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test meals with increasing unsaturation
Number of subjects: 18
Study: 9702314

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Polysulfone
Number of subjects: 197

Group type: COMPARATOR
Intervention: Both PAN and polysulfone
Number of subjects: 197
Study: 7520210

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 and 25 mg/day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 186
Study: 2784585

Group type: EXPERIMENTAL
Intervention: Tampon use
Number of subjects: 35

Group type: COMPARATOR
Intervention: Napkin use
Number of subjects: 35
Study: 31948507

Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary program for depression care in nursing homes
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Specific program components used in treatment procedures
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Assessment procedures
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Monitoring procedures
Number of subjects: 796
Study: 31021980

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 35 mg orally twice a day for three months, in addition to conventional treatments for angina.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional treatments for angina only.
Number of subjects: 58
Study: 28499583

Group type: COMPARATOR
Intervention: Standard chemotherapy (epirubicin 60 mg/m2 per day plus ifosfamide 3 g/m2 per day, repeated every 21 days)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Histotype-tailored chemotherapy (various regimens based on histological subtype)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Histotype-tailored chemotherapy
Number of subjects: 287
Study: 26944817

Group type: EXPERIMENTAL
Intervention: 18-month low-magnitude high-frequency vibration (LMHFV)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 59
Study: 24183196

Group type: EXPERIMENTAL
Intervention: Warmed irrigation solution at 32°C ± 2°C (89.6°F ± 3.6°F)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Room temperature irrigation solution (Control)
Number of subjects: 166
Study: 22099625

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 116

Group type: COMPARATOR
Intervention: Esmolol vs Nicardipine
Number of subjects: 116
Study: 19643224

Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate (PMMA) / double-cross linked PMMA fillers (35%/59% SR Antaris DCL, SR Postaris DCL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experimental artificial tooth material (48%/46%)
Number of subjects: 28